|
⚲
|
| Keyboard |
| SV7 Imf GP Llp | |
|---|---|
| Firm | SV Health Managers LLP |
| Address | 71 Kingsway London, X0 WC2B 6ST |
| Source |
| Associated Funds | Form D | Role | 2011 - 2026 | Raised | AUM |
|---|---|---|---|---|---|
| SV Health Managers LLP | |||||
| SV7 Impact Medicine Fund LP | 021-342712 | Executive Officer | of 250.0 M |
296.9 M | |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Xilio Therapeutics Inc XLO
Common Stock
|
2021-10-26 | Conversion | 998,544 | ||
|
Xilio Therapeutics Inc XLO
Common Stock
|
2021-10-26 | Conversion | 998,544 | ||
|
Xilio Therapeutics Inc XLO
Common Stock
|
2021-10-26 | Conversion | 302,588 | ||
|
Xilio Therapeutics Inc XLO
Common Stock
|
2021-10-26 | Conversion | 302,588 | ||
|
Xilio Therapeutics Inc XLO
Series B Convertible Preferred Stock · derivative
|
2021-10-26 | Conversion | 9,486,166 | $0.00 | |
|
Xilio Therapeutics Inc XLO
Series C Convertible Preferred Stock · derivative
|
2021-10-26 | Conversion | 2,874,595 | $0.00 | |
|
Xilio Therapeutics Inc XLO
Series B Convertible Preferred Stock · derivative
|
2021-10-26 | Conversion | 9,486,166 | $0.00 | |
|
Xilio Therapeutics Inc XLO
Series C Convertible Preferred Stock · derivative
|
2021-10-26 | Conversion | 2,874,595 | $0.00 |